- Home
- QH vs ZNTL Comparison
QH vs ZNTL Comparison
Compare QH & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- ZNTL
- Stock Information
- Founded
- QH 2012
- ZNTL 2014
- Country
- QH China
- ZNTL United States
- Employees
- QH N/A
- ZNTL N/A
- Industry
- QH Business Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- QH Consumer Discretionary
- ZNTL Health Care
- Exchange
- QH Nasdaq
- ZNTL Nasdaq
- Market Cap
- QH 115.7M
- ZNTL 105.8M
- IPO Year
- QH 2020
- ZNTL 2020
- Fundamental
- Price
- QH $0.12
- ZNTL $1.44
- Analyst Decision
- QH
- ZNTL Buy
- Analyst Count
- QH 0
- ZNTL 7
- Target Price
- QH N/A
- ZNTL $8.46
- AVG Volume (30 Days)
- QH 18.4M
- ZNTL 570.1K
- Earning Date
- QH 08-27-2025
- ZNTL 08-06-2025
- Dividend Yield
- QH N/A
- ZNTL N/A
- EPS Growth
- QH N/A
- ZNTL N/A
- EPS
- QH 0.01
- ZNTL N/A
- Revenue
- QH $417,431,053.00
- ZNTL $26,865,000.00
- Revenue This Year
- QH N/A
- ZNTL N/A
- Revenue Next Year
- QH N/A
- ZNTL N/A
- P/E Ratio
- QH $13.26
- ZNTL N/A
- Revenue Growth
- QH N/A
- ZNTL N/A
- 52 Week Low
- QH $0.09
- ZNTL $1.01
- 52 Week High
- QH $2.27
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- QH 22.24
- ZNTL 55.02
- Support Level
- QH $0.09
- ZNTL $1.35
- Resistance Level
- QH $0.14
- ZNTL $1.45
- Average True Range (ATR)
- QH 0.11
- ZNTL 0.08
- MACD
- QH -0.08
- ZNTL 0.00
- Stochastic Oscillator
- QH 1.62
- ZNTL 54.19
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.